title: MLN-02 in IBD: is "super-selective" really super?
authors.forename: Russell D
authors.initials: RD
authors.lastname: Cohen
mesh_terms: D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy; D016177:Macrophage-1 Antigen / Q000008:administration & dosage*; D008297:Male; D012016:Reference Values; D018570:Risk Assessment; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D016177:Macrophage-1 Antigen